906 results on '"Pallansch, Mark A"'
Search Results
2. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial
3. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020
4. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial
5. Progress Toward Poliovirus Containment Implementation — Worldwide, 2019–2020
6. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial
7. Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world
8. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
9. Progress in poliovirus containment--worldwide, 2019-2020/Progres du confinement des poliovirus dans le monde, 2019-2020
10. Increase in Acute Flaccid Myelitis — United States, 2018
11. Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models : Support for at least 2 Doses
12. The seasonality of nonpolio enteroviruses in the United States : Patterns and drivers
13. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial
14. Update on vaccine-derived Polioviruses--worldwide, January 2018-June 2019/Le point sur les poliovirus derives d'une souche vaccinale dans le monde, janvier 2018-juin 2019
15. Outbreak of Neurologic Enterovirus Type 71 Disease: A Diagnostic Challenge
16. Emergence of Echovirus Type 13 as a Prominent Enterovirus
17. The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks
18. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
19. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
20. Worst‐case scenarios: Modeling uncontrolled type 2 polio transmission
21. An Echovirus Type 33 Winter Outbreak in New Zealand
22. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
23. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule
24. Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus
25. Worst‐case scenarios: Modeling uncontrolled type 2 polio transmission.
26. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
27. Deaths of Children during an Outbreak of Hand, Foot, and Mouth Disease in Sarawak, Malaysia: Clinical and Pathological Characteristics of the Disease
28. Viral Meningitis in Child Care Center Staff and Parents: An Outbreak of Echovirus 30 Infections
29. Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance
30. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial
31. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation
32. Expansion of syndromic vaccine preventable disease surveillance to include bacterial meningitis and Japanese encephalitis: Evaluation of adapting polio and measles laboratory networks in Bangladesh, China and India, 2007–2008
33. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems
34. CDC's Early Response to a Novel Viral Disease, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), September 2012-May 2014
35. Modeling Options to Manage Type 1 Wild Poliovirus Imported Into Israel in 2013
36. Update on the Epidemiology of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection, and Guidance for the Public, Clinicians, and Public Health Authorities — January 2015
37. Polio Eradicators Use Integrated Analytical Models to Make Better Decisions
38. Clinical and Laboratory Findings of the First Imported Case of Middle East Respiratory Syndrome Coronavirus to the United States
39. Circulating Poliovirus in New York — New Instance of an Old Problem
40. Outbreak response strategies with type 2-containing oral poliovirus vaccines
41. Survey of poliovirus antibodies in Kano, Northern Nigeria
42. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea
43. Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description
44. Effect of Buffer on the Immune Response to Trivalent Oral Poliovirus Vaccine in Bangladesh: A Community Based Randomized Controlled Trial
45. A World Without Polio
46. Outbreak of Type 1 Wild Poliovirus Infection in Adults, Namibia, 2006
47. Detection of Vaccine-Derived Polioviruses in Mexico Using Environmental Surveillance
48. Assessing Population Immunity in a Persistently High-Risk Area for Wild Poliovirus Transmission in India: A Serological Study in Moradabad, Western Uttar Pradesh
49. Progress in the Development of Poliovirus Antiviral Agents and Their Essential Role in Reducing Risks That Threaten Eradication
50. Prevalence of Asymptomatic Poliovirus Infection in Older Children and Adults in Northern India: Analysis of Contact and Enhanced Community Surveillance, 2009
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.